BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36371989)

  • 1. Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.
    Robinson JI; Md Yusof MY; Davies V; Wild D; Morgan M; Taylor JC; El-Sherbiny Y; Morris DL; Liu L; Rawstron AC; Buch MH; Plant D; Cordell HJ; Isaacs JD; Bruce IN; Emery P; Barton A; Vyse TJ; Barrett JH; Vital EM; Morgan AW; ;
    EBioMedicine; 2022 Dec; 86():104343. PubMed ID: 36371989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
    Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
    J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of FCGR3A and FCGR3B copy number variations with systemic lupus erythematosus and rheumatoid arthritis in Taiwanese patients.
    Chen JY; Wang CM; Chang SW; Cheng CH; Wu YJ; Lin JC; Yang B; Ho HH; Wu J
    Arthritis Rheumatol; 2014 Nov; 66(11):3113-21. PubMed ID: 25154742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.
    Dall'Ozzo S; Tartas S; Paintaud G; Cartron G; Colombat P; Bardos P; Watier H; Thibault G
    Cancer Res; 2004 Jul; 64(13):4664-9. PubMed ID: 15231679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
    Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
    Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
    Cartron G; Dacheux L; Salles G; Solal-Celigny P; Bardos P; Colombat P; Watier H
    Blood; 2002 Feb; 99(3):754-8. PubMed ID: 11806974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis.
    Thabet MM; Huizinga TW; Marques RB; Stoeken-Rijsbergen G; Bakker AM; Kurreeman FA; White SJ; Toes RE; van der Helm-van Mil AH
    Ann Rheum Dis; 2009 Nov; 68(11):1775-80. PubMed ID: 19019892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
    Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
    Front Immunol; 2019; 10():390. PubMed ID: 30899264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic HIV-1 Infection Alters the Cellular Distribution of FcγRIIIa and the Functional Consequence of the FcγRIIIa-F158V Variant.
    Phaahla NG; Lassaunière R; Da Costa Dias B; Waja Z; Martinson NA; Tiemessen CT
    Front Immunol; 2019; 10():735. PubMed ID: 31024562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
    Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
    Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
    Jiménez Morales A; Maldonado-Montoro M; Martínez de la Plata JE; Pérez Ramírez C; Daddaoua A; Alarcón Payer C; Expósito Ruiz M; García Collado C
    J Clin Pharmacol; 2019 Apr; 59(4):517-531. PubMed ID: 30457672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.
    Anolik JH; Campbell D; Felgar RE; Young F; Sanz I; Rosenblatt J; Looney RJ
    Arthritis Rheum; 2003 Feb; 48(2):455-9. PubMed ID: 12571855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma.
    Liu F; Ding H; Jin X; Ding N; Deng L; He Y; Zhu J; Song Y
    DNA Cell Biol; 2014 Sep; 33(9):616-23. PubMed ID: 25050883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
    Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells.
    Erbe AK; Wang W; Gallenberger M; Hank JA; Sondel PM
    Methods Mol Biol; 2016; 1441():43-56. PubMed ID: 27177655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
    Quartuccio L; Fabris M; Pontarini E; Salvin S; Zabotti A; Benucci M; Manfredi M; Biasi D; Ravagnani V; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Tomietto P; Bazzichi L; Saracco M; Pellerito R; Cimmino M; Schiavon F; Carraro V; Semeraro A; Caporali R; Cavagna L; Bortolotti R; Paolazzi G; Govoni M; Bombardieri S; De Vita S
    Ann Rheum Dis; 2014 Apr; 73(4):716-21. PubMed ID: 23505228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
    Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
    Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
    Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B.
    Morgan AW; Barrett JH; Griffiths B; Subramanian D; Robinson JI; Keyte VH; Ali M; Jones EA; Old RW; Ponchel F; Boylston AW; Situnayake RD; Markham AF; Emery P; Isaacs JD
    Arthritis Res Ther; 2006; 8(1):R5. PubMed ID: 16356189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab.
    Ajeganova S; Tesfa D; Hägglund H; Fadeel B; Vedin I; Zignego AL; Palmblad J
    Arthritis Res Ther; 2017 Mar; 19(1):44. PubMed ID: 28270182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.